This interview discusses Little Green Pharma’s (ASX:LGP) record-breaking quarterly results for June 2024, highlighting a 12% increase in revenue and significant cash receipts. CEO Paul Long elaborates on the company’s growth drivers, including new product sales in Australia and Europe, and outlines their strategy to maintain market share and expand in emerging European markets.
More From The Market Online
Provaris Energy’s hydrogen tanker fabrication to recommence; shares up 6%
Provaris (ASX:PV1) has announced fabrication of its prototype hydrogen tanker is to recommence in 2025, pushing…
- Jonathon Davidson
- 2 mins
- 20 December 2024 17:37 (AEDT)
Little Green Pharma jumps into distribution with acquisition
Little Green Pharma is aiming to make the strategic acquisition of HH (Australia) Pty Ltd to…
- Caroline Smith
- 1 min
- 20 December 2024 13:46 (AEDT)
ASX Market Update: Index sheds another 1% as Discretionary stocks lead broad selloff | December 20, 2024
The ASX200 has been down 1% at 8,084 points.
- Sean Boss
- 2 mins
- 20 December 2024 13:39 (AEDT)
‘Meaningful step towards our target’: Cleanaway JV opens door to monetising landfill gas
Cleanaway Waste Management has entered a joint venture with LMS Energy Pty Ltd to enable landfill…
- Caroline Smith
- 2 mins
- 20 December 2024 10:03 (AEDT)